Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacopeia and GSK alliance identifies new drug compound
This newly identified lead compound is from a program being evaluated as a potential treatment for inflammatory pain and is the sixth lead compound identified through the collaboration.
This newly identified lead compound is from a program being evaluated as a potential treatment for inflammatory pain and is the sixth lead compound identified through the collaboration.
The randomized, double-blind, placebo-controlled, international Phase III trial is designed to evaluate the therapeutic benefit of Rebif (interferon beta-1a) on the time to conversion to multiple sclerosis (MS)
Earlier preclinical data showed that enzyme replacement therapy with Enobia’s product ENB-0040, significantly increases survival and prevents bone hypomineralization associated with hypophosphatasia, a rare genetic bone disease. In
Study results show that approximately half of patients who received ipilimumab (10mg/kg) remained alive beyond one year. The results are based on follow-up of the patient population from
In the 12-week placebo-controlled study, known as the Sirocco trial, neither the active comparator donepezil nor AZD3480 met the trial’s criteria for statistical significance on the primary outcome
Results from a Phase II, randomized, non-comparative study showed that 54% of patients with stage III/IV treatment-naive NSCLC receiving the combination CP-751,871 plus carboplatin and paclitaxel (n=97) experienced
The interim data demonstrated that treatment with the proprietary recombinant full-length human parathyroid hormone (PTH 1-84) had a beneficial effect on abnormal bone skeletal properties in patients with
Calando’s first siRNA therapeutic, CALAA-01, which targets the M2 subunit of ribonucleotide reductase, is currently in a Phase I clinical trial. Calando intends to move CALAA-02 into the
In his new position, Mr Barr will be responsible for the continued features and capabilities expansion of Prism, Nextrials’s clinical trial management software and electronic data capture solution.
According to the company, this new system represents the best of both worlds for skin resurfacing, as it combines the effectiveness of an ablative approach with the patient